drugset / Trial / NCT00127192

A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

NCT00127192

Phase 2 Completed 363 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with type 2 diabetes mellitus.

Timeline

Start
2005-07
Primary completion
2006-03
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 25 mg Oral
Subject Sitagliptin Small molecule 50 mg Oral
Subject Sitagliptin Small molecule 100 mg Oral
Subject Sitagliptin Small molecule 200 mg Oral